Apyx Medical Corp Cash Flow Statement
APYX|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Apyx Medical Corp used $8M in operating cash flow and negative free cash flow of $9M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.02 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$11.2M | -$23.5M | -$23.2M | -$23.2M | -$11.9M | -$19.7M | -$5.1M | -$11.6M | -$5.4M | -$17.3M | -$4.3M | $617.0K | $109.0K | -$1.5M | $596.0K |
| Depreciation & Amortization | $655.0K | $599.0K | $890.0K | $890.0K | $887.0K | $754.0K | $696.0K | $734.0K | $812.0K | $876.0K | $827.0K | $742.0K | $753.0K | $734.0K | $777.0K |
| Operating Cash Flow | -$8.0M | -$18.0M | -$20.3M | -$20.3M | -$16.1M | -$18.5M | -$3.7M | -$2.8M | -$5.8M | -$417.0K | -$2.5M | $165.0K | $1.9M | -$526.0K | -$97.0K |
| Capital Expenditures | $1.1M | $722.0K | $1.0M | $1.0M | $581.0K | $1.3M | $624.0K | $286.0K | $421.0K | $630.0K | $588.0K | $753.0K | $542.0K | $201.0K | $2.5M |
| Free Cash Flow | -$9.1M | -$18.8M | -$21.3M | -$21.3M | -$16.6M | -$19.8M | -$4.3M | -$3.1M | -$6.2M | -$1.0M | -$3.1M | -$588.0K | $1.4M | -$727.0K | -$2.6M |
| FCF Margin | -17.3% | -39.0% | -47.8% | -47.8% | -60.1% | -70.0% | -42.3% | -35.4% | -21.0% | -3.8% | -13.2% | -9.1% | 5.3% | -3.0% | -9.5% |